Thomas C. Meyers

OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ.

Real Time Genomics, Inc. develops genomic analysis solutions. It offers software tools and applications for the extraction of unique value from genomic data. The company was founded by Graham Gaylard, Mike Okura, Stephen J. Lombardi and Stuart Inglis in 2009 and is headquartered San Bruno, CA.

GnuBIO, Inc. develops life science research and clinical diagnostics products. It develops a droplet-based DNA sequencing technology that integrates the entire sample preparation workflow on a chip, from sample capture, PCR, and sequencing to informatics for researchers and clinicians. The company was founded by David A. Weitz, John J. Boyce, IV and Michael P. Weiner and is headquartered in Cambridge, MA.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.

Part of Quest Diagnostics, Inc., Shanghai GeneCore BioTechnologies Co., Ltd. engages in nucleotide synthesis, DNA sequencing, bioinformatics analysis, and mutation detection. The company is based in Shanghai, China.

Central Hockey League operates a professional minor league hockey teams playing in small to medium-sized markets primarily in central and southwestern US states. The league, which was started in 1992, is managed and operated by WPHL, a subsidiary of Global Entertainment Corporation.

International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA.

Rosetta Biosoftware is a private company that provides software solutions for life science research. The company is based in Seattle, WA. The company's software helps researchers analyze and manage large amounts of data related to genomics, proteomics, and other life science fields. The company offers a range of products and services, including data analysis software, consulting services, and training programs. The company's software is designed to be user-friendly and customizable, allowing researchers to tailor it to their specific needs.

C.L.A.S.S., Inc. is a non-profit organization provides support to adults with autism and intellectual/developmental disabilities. It offers employment, autism services support, day habilitation, community-based day services, and clinical and case management support. The company was founded in 1976 and is headquartered in Lawrence, MA.

Ethicon Corp. manufactures and markets surgical sutures. The company is headquartered in Somerville, NJ.

Molecular Assemblies, Inc. develops an enzymatic deoxyribonucleic acid (DNA) synthesis technology designed to power the next generation of DNA-based products. The firm's technology will enable the reading and writing of DNA for industries including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. The company was founded by William Efcavitch and Curt Becker in 2013 and is headquartered in San Diego, CA.

Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA.

Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA.

Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA.

Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018.

Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023.

Profound Therapeutics is a company that is focused on discovering new medicines by expanding the human proteome. The company is based in Cambridge, MA. The company uses their platform, Profoundry, to identify and validate proteins and understand their therapeutic potential. This results in a growing database of novel proteins and their roles in health and disease. The company was founded in 2020 by Avak Kahvejian, who has been the CEO since then.

Ampersand Biomedicines is an American company that designs programmable medicines that work precisely where needed in the body and nowhere else. The company's computationally powered platform identifies ideal addresses for drug localization and informs the design of and-body™ therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability. The company was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering. Jason Gardner has been the CEO of the company since 2023.